New Alzheimer’s Blood Test Revolutionizes Diagnosis

A groundbreaking blood test that identifies a key indicator of Alzheimer’s is on the horizon, set to transform how doctors diagnose and manage the condition.

This innovative test, the first approved by the Food and Drug Administration, is intended for individuals aged 55 and over who are experiencing memory issues or signs of Alzheimer’s. The test results reveal whether a person exhibits amyloid plaques—clumps of toxic proteins that accumulate between the brain’s cells. Typically, finding these plaques alongside cognitive symptoms confirms an Alzheimer’s diagnosis.

According to Dr. Howard Fillit, chief science officer at the Alzheimer’s Drug Discovery Foundation, this blood test could significantly enhance the care and diagnosis of Alzheimer’s patients. He believes that primary care providers will now have a tool that offers quicker insights into whether someone has the disease.

Maria Carrillo, chief science officer of the Alzheimer’s Association, echoes this sentiment, noting that thanks to this test, physicians will gain access to results that can expedite the diagnostic process. Currently, primary care doctors can accurately diagnose Alzheimer’s in only about 60% of cases, making the potential for improvement significant.

Fillit emphasizes the advantage of greater accuracy with the blood test. While specialists have a higher diagnostic accuracy rate—around 70 to 80%—the integration of this test could push that number beyond 90%.

Currently, PET scans are considered the gold standard for spotting amyloid plaques associated with Alzheimer’s, but the expense and scarcity of this technology in many areas limit its accessibility. Additionally, spinal taps, which are invasive, are often avoided by both medical staff and patients.

Although some lab-developed blood tests indicating amyloid presence already exist, the Lumipulse assay developed by Fujirebio is unique as it has received FDA marketing clearance. This means that diagnosis could occur earlier, potentially when symptoms are still manageable.

A recent survey conducted by the Alzheimer’s Association revealed that a large majority of older Americans would consider taking a blood test if it would confirm an Alzheimer’s diagnosis. Those diagnosed early may benefit from one of the amyloid-reducing medications currently available.

For the most part, lab-developed blood tests have been largely restricted to researchers and specialists in large hospitals, but with this FDA-approved test, a wider audience is anticipated. Carrillo points out that the test has undergone thorough evaluation, providing prescribers with crucial guidance on who should undergo testing and when.

This breakthrough is expected to result in increased testing, particularly among those in rural or underserved communities. Carrillo believes blood tests can significantly democratize Alzheimer’s testing, which means that many of the estimated 7.2 million Americans living with the disease may finally receive a formal diagnosis.

To assist healthcare providers in discussing the test results with patients, the Alzheimer’s Association is preparing guidelines aimed at explaining the implications of a diagnosis, how to live with the disease, and what treatment options exist. These guidelines are slated for release this summer.